Switch theme
Sign up to access all valuation multiples
Mouwasat Medical Services Co is engaged in the acquisition, management, operation, and maintenance of hospitals, medical centers, drug stores, pharmacies, and wholesale of medical equipment and drugs. The company also operates skin care centers that offer clinical and cosmetic dermatology, aesthetic and reconstructive plastic surgery, weight reduction, and esthetician services. It operates in two segments Medical Services segment and Pharmaceuticals out of which the Medical Services segment derives the majority of revenue.
1997
4.1K+
LTM Revenue $803M
LTM EBITDA $273M
$3.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mouwasat has a last 12-month revenue (LTM) of $803M and a last 12-month EBITDA of $273M.
In the most recent fiscal year, Mouwasat achieved revenue of $769M and an EBITDA of $260M.
Mouwasat expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mouwasat valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $803M | XXX | $769M | XXX | XXX | XXX |
| Gross Profit | $354M | XXX | $344M | XXX | XXX | XXX |
| Gross Margin | 44% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | $273M | XXX | $260M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBIT | $204M | XXX | $209M | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $182M | XXX | $172M | XXX | XXX | XXX |
| Net Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $83.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mouwasat's stock price is SAR 73 (or $19).
Mouwasat has current market cap of SAR 14.5B (or $3.9B), and EV of SAR 14.6B (or $3.9B).
See Mouwasat trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.9B | $3.9B | XXX | XXX | XXX | XXX | $0.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mouwasat has market cap of $3.9B and EV of $3.9B.
Mouwasat's trades at 5.1x EV/Revenue multiple, and 15.0x EV/EBITDA.
Equity research analysts estimate Mouwasat's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mouwasat has a P/E ratio of 21.3x.
See valuation multiples for Mouwasat and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.9B | XXX | $3.9B | XXX | XXX | XXX |
| EV (current) | $3.9B | XXX | $3.9B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | 14.3x | XXX | 15.0x | XXX | XXX | XXX |
| EV/EBIT | 19.1x | XXX | 18.7x | XXX | XXX | XXX |
| EV/Gross Profit | 11.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.3x | XXX | 22.5x | XXX | XXX | XXX |
| EV/FCF | 21.1x | XXX | 17.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMouwasat's last 12 month revenue growth is 11%
Mouwasat's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $33K for the same period.
Mouwasat's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mouwasat's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mouwasat and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 3% | XXX | XXX | XXX |
| Rule of 40 | 48% | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mouwasat acquired XXX companies to date.
Last acquisition by Mouwasat was XXXXXXXX, XXXXX XXXXX XXXXXX . Mouwasat acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mouwasat founded? | Mouwasat was founded in 1997. |
| Where is Mouwasat headquartered? | Mouwasat is headquartered in Saudi Arabia. |
| How many employees does Mouwasat have? | As of today, Mouwasat has 4.1K+ employees. |
| Who is the CEO of Mouwasat? | Mouwasat's CEO is Mr. Nasser Sultan Fahed Al-Subaie. |
| Is Mouwasat publicy listed? | Yes, Mouwasat is a public company listed on SAU. |
| What is the stock symbol of Mouwasat? | Mouwasat trades under 4002 ticker. |
| When did Mouwasat go public? | Mouwasat went public in 2009. |
| Who are competitors of Mouwasat? | Similar companies to Mouwasat include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Mouwasat? | Mouwasat's current market cap is $3.9B |
| What is the current revenue of Mouwasat? | Mouwasat's last 12 months revenue is $803M. |
| What is the current revenue growth of Mouwasat? | Mouwasat revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Mouwasat? | Current revenue multiple of Mouwasat is 4.9x. |
| Is Mouwasat profitable? | Yes, Mouwasat is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mouwasat? | Mouwasat's last 12 months EBITDA is $273M. |
| What is Mouwasat's EBITDA margin? | Mouwasat's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Mouwasat? | Current EBITDA multiple of Mouwasat is 14.3x. |
| What is the current FCF of Mouwasat? | Mouwasat's last 12 months FCF is $185M. |
| What is Mouwasat's FCF margin? | Mouwasat's last 12 months FCF margin is 23%. |
| What is the current EV/FCF multiple of Mouwasat? | Current FCF multiple of Mouwasat is 21.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
